👥
0
🟢
0
Onchocerciasis Market: Is Moxidectin Set to Disrupt Three Decades of Ivermectin Dominance in River Blindness Control?
Moxidectin's emergence in onchocerciasis treatment — the next-generation macrocyclic lactone achieving 86% greater parasite clearance than ivermectin at one year post-treatment and requiring fewer mass drug administration rounds — represents the most significant therapeutic innovation in river blindness management since Merck's Mectizan donation program began in 1987, with the...
0 Comments 0 Shares 11 Views 0 Reviews
Sponsored

Ask ME!

Meet @froq — your AI companion for instant answers, smart conversations, creative ideas, and real-time help. Just mention @froq and start chatting. 🚀